ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Buspar®:Bristol-Myers Squibb SA
Complete information for professionalsDDDPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
Registration ownerLast update of information 
N05BE01 - BuspironeATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N05 - Psycholeptics

The group is divided into therapeutic subgroups:
N05A - Antipsychotics
N05B - Anxiolytics
N05C - Hypnotics and sedatives

N05B - Anxiolytics

This group comprises preparations used in the treatment of neuroses and psychosomatic disorders associated with anxiety and tension, e.g. benzodiazepines.
See also:
N05A - Antipsychotics
N05C - Hypnotics and sedatives
Usually the presence of an anxiolytic (or other psycholeptics) in combined preparations must be regarded as being of secondary importance and the preparations should be classified in the respective therapeutic groups (e.g. A03C - Antispasmodics in combination with psycholeptics, N02 - Analgesics).
Combined preparations used mainly for the treatment of anxiety are classified at separate 5th levels using the corresponding 50-series.
The group is subdivided according to chemical structure.

The DDDs are based on the treatment of anxiety.

N05BE - Azaspirodecanedione Derivatives
 
N05BE01 - Buspirone
DoseRoute of administrationNote
 O 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home